Combined inhibition of CDK4/6 and AKT is effective in Rb-intact triple-negative breast cancer of the luminal androgen receptor (LAR) subtype

被引：0
|
作者：
Kim, Gun Min
Lee, Kyung-min
Sudhan, Dhivya
Lin, Albert
Marin, Arnaldo
Chatterjee, Sumanta
Ye, Dan
Kandagatla, Vishal
Mendiratta, Saurabh
Hanker, Ariella
Arteaga, Carlos
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-PD3-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD3-07
引用
收藏
页数：3
相关论文
共 50 条
  • [41] CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
    Saleh, Lubaid
    Wilson, Caroline
    Holen, Ingunn
    MEDCOMM, 2021, 2 (04): : 514 - 530
  • [42] Palbociclib, a CDK4/6 inhibitor, suppresses proliferation of triple negative breast cancer
    Min, Ahrum
    Kim, Yu Jin
    Hang, Hyemin
    Lim, Jee Min
    Kim, Seongyeong
    Kim, So Hyeon
    Suh, Koung Jin
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Im, Seock-Ah
    CANCER RESEARCH, 2018, 78 (13)
  • [43] Combination of CDK4/6 inhibitors with biguanides for treatment of triple negative breast cancer
    Martinez, Mario Morales
    Gonzalez, Eduardo Mauricio
    Deng, Gang
    Ma, Gaoyuan
    Kim, Hyunsoo
    Stiles, Linsey
    Hamilton, Nalo
    Jung, Michael E.
    Pietras, Richard J.
    Marquez-Garban, Diana C.
    CANCER RESEARCH, 2024, 84 (06)
  • [44] Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
    Schedin, Troy B.
    Borges, Virginia F.
    Shagisultanova, Elena
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2018, 2018
  • [45] CDK4/6 inhibition blocks effects of IGFs and insulin in estrogen receptor positive and triple negative breast cancers
    Hoff, Katelyn
    Sachdev, Deepali
    CANCER RESEARCH, 2018, 78 (13)
  • [46] Anti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer
    Khadela, Avinash
    Chavda, Vivek P. P.
    Soni, Shruti
    Megha, Kaivalya
    Pandya, Aanshi J. J.
    Vora, Lalitkumar
    CANCERS, 2023, 15 (01)
  • [47] A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers
    Safarpour, Damoun
    Tavassoli, Fattaneh A.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (05) : 612 - 617
  • [48] CREBBP alterations lead to CDK4/6 inhibitor sensitivity in triple negative breast cancer
    Natrajan, Rachael
    CANCER RESEARCH, 2020, 80 (04)
  • [49] Phase IB/II trial of palbociclib and binimetinib in advanced triple-negative breast cancer with hyperactivation of ERK and/or CDK4/6
    Manso, Luis
    Cortes, Alfonso
    Cejalvo, Juan M.
    Morales, Serafin
    Saenz, Jose A. Garcia
    Colomer, Ramon
    Sanchez-Bayona, Rodrigo
    Silva, Jorge
    Guerra, Juan A.
    Malon, Diego
    Mouron, Silvana
    Caleiras, Eduardo
    Quintela-Fandino, Miguel
    CANCER RESEARCH, 2022, 82 (04)
  • [50] Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
    Christenson, Jessica L.
    O'Neill, Kathleen, I
    Williams, Michelle M.
    Spoelstra, Nicole S.
    Jones, Kenneth L.
    Trahan, G. Devon
    Reese, Jordan
    van Patten, Elaina T.
    Elias, Anthony
    Eisner, Joel R.
    Richer, Jennifer K.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (06) : 1062 - 1071
12345